Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape.
Starr TN, Czudnochowski N, Zatta F, Park YJ, Liu Z, Addetia A, Pinto D, Beltramello M, Hernandez P, Greaney AJ, Marzi R, Glass WG, Zhang I, Dingens AS, Bowen JE, Wojcechowskyj JA, De Marco A, Rosen LE, Zhou J, Montiel-Ruiz M, Kaiser H, Tucker H, Housley MP, di Iulio J, Lombardo G, Agostini M, Sprugasci N, Culap K, Jaconi S, Meury M, Dellota E, Cameroni E, Croll TI, Nix JC, Havenar-Daughton C, Telenti A, Lempp FA, Pizzuto MS, Chodera JD, Hebner CM, Whelan SPJ, Virgin HW, Veesler D, Corti D, Bloom JD, Snell G.
Starr TN, et al.
bioRxiv [Preprint]. 2021 Apr 8:2021.04.06.438709. doi: 10.1101/2021.04.06.438709.
bioRxiv. 2021.
PMID: 33851154
Free PMC article.
Updated.
Preprint.